Fund: GSFHC
| Goldman Sachs Future Health Care Equity ETF (dis) | |
| US38149W7700 | |
| 09-11-2021 | |
| Equity | |
| Equity Sectors - Health Care | |
| Goldman Sachs | |
| Goldman Sachs Asset Management, L.P. | |
| USD | |
| 1,000 | |
| 5% |
| 1M | 3M | 6M | 9M | 1R | 3R p.a. | 5R p.a. | 7R p.a. | 10R p.a. | od vnizku p.a. | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Výkonnosť fondu | -4.05% | 0.83% | 12.62% | -1.31% | -0.87% | - | - | - | - | N/A | |
| Priemerná výkonnosť (36 meraní) | - | - | - | - | - | ||||||
| Volatilita od priemernej výkonnosti | - | - | - | - | - |
| Long | Short | Net | |
|---|---|---|---|
| Stock | 97.95% | 97.95% | |
| Bond | |||
| Other | |||
| Cash | 2.05% | 2.05% |
| Aktíva | 261 mil. |
| Počet akcíí | 47 |
| Počet dlhopisov | 0 |
| Priebež. popl. | |
| z toho Mng. popl. | 0.75 |
| Výk. prémia | |
| Trans. popl. |
| Dividenda | 0.716 |
| Dividendový výnos | 2.14% |
| Rozhodný dátum | 26-12-2023 |
| Frekvencia výplaty | štvrťročne |
| Giant | 27.92% |
| Large | 27.09% |
| Medium | 38.74% |
| Small | 3.76% |
| Micro | 0.44% |
| P/E | 28.38% |
| P/BV | 4.97% |
| Healthcare | 96.92% |
| Technology | 1.04% |
| Derivatives | 2.05 |
| Výnos do splatnosti p.a. | |
| Modifikovaná durácia |
| United States | 73.05% |
| Canada | 0.50% |
| Latin America | |
| United Kingdom | 6.50% |
| Eurozone | 1.34% |
| Europe - ex Euro | 8.76% |
| Europe - Emerging | |
| Africa | |
| Middle East | |
| Japan | 5.07% |
| Australasia | 2.74% |
| Asia - Developed | |
| Asia - Emerging | |
| Emerging Market | |
| Developed Country | 97.95% |
| Not Classified |
| Spoločnosť | Subsektor | Váha | Spoločnosť | Subsektor | Váha |
|---|---|---|---|---|---|
| Eli Lilly and Co | Healthcare | 9.82% | Novo Nordisk A/S Class B | Healthcare | 5.73% |
| Boston Scientific Corp | Healthcare | 5.45% | AstraZeneca PLC | Healthcare | 5.44% |
| Intuitive Surgical Inc | Healthcare | 4.46% | Danaher Corp | Healthcare | 3.55% |
| The Cooper Companies Inc | Healthcare | 3.48% | Zimmer Biomet Holdings Inc | Healthcare | 3.44% |
| Amgen Inc | Healthcare | 3.4% | Biomarin Pharmaceutical Inc | Healthcare | 3.14% |